. Author manuscript; available in PMC: 2014 May 2.

Published in final edited form as: Pediatr Blood Cancer. 2012 Apr 5;59(5):834–839. doi: 10.1002/pbc.24132

TABLE I.

COG P9407 Induction and Induction Intensification Therapy and Modifications

Cohort 1 (1996–1997)	Cohort 2 (1997–2000)		Cohort 3 (2001–2006)
June 1996	November 1997	July 1998	Jan 2001
TIT^a days 1, 8, 15, 22, 29
VCR 0.05 mg/kg, days 1, 15; VCR 0.03 mg/kg, day 8
Dex 10 mg/m²/day div TID, days 1–21			PDN 40 mg/m²/day div TID, days 1–21
Daun days 1, 2	Daun days 1, 2	Daun days 1, 2	Daun days 1, 2
All ages—120 mg/m² CI over 48 hours		≤90 days 2 mg/kg/day IV over 30 minutes
	<6 months at diagnosis 2 mg/kg/day CI	>90 days to <6 months 2 mg/kg/day CI	<6 months 2 mg/kg/day IV over 30 minutes
	6 to <9 months 2.5 mg/kg/day CI	6 to <9 months 2.5 mg/kg/day CI	6 to <9 months 2.5 mg/kg/day IV over 30 minutes
	≥9 months 3 mg/kg/day CI	≥9 months 3 mg/kg/day CI	≥9 months 3 mg/kg/day IV over 30 minutes
Cy 250 mg/m² every 12 hours × 4 doses, days 3, 4 (with MESNA)
Asp 6,000 U/m² IM days 4, 6, 8, 10, 12, 15, 17, 19
HD MTX 4 g/m² over 24 hours days 22, 29 (followed by leucovorin rescue)
VP-I6 100 mg/m²/day days 36–40
Cy 300 mg/m²/day days 36–40 (with MESNA)

TIT to <365 days of age—intrathecal methotrexate 7.5 mg, hydrocortisone 7.5 mg, cytosine arabinoside 15 mg; >365 days of age—intrathecal methotrexate 8 mg, hydrocortisone 8 mg, cytosine arabinoside 16 mg; VCR—vincristine; Dex—dexamethasone; Daun—daunorubicin; Cy—cyclophosphamide; Asp—native L-asparaginase; HD MTX—high dose methotrexate; VP-16—etoposide; PDN—prednisone; TID—three times daily; CI—continuous infusion; Leucovorin rescue beginning 42 hours after start of HD MTX infusion—10 mg/m² every 6 hours for five doses.